Targeted treatment approaches in refractory germ cell tumors

A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors. Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT01962896. A Study of Atezolizumab in Advanced Solid Tumors. Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT02458638. Adra, 2018, Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer research Network Study GU14-206, Ann. Oncol., 29, 209, 10.1093/annonc/mdx680 Albany, 2013, Antitumor activity of brentuximab vedotin in CD30 positive refractory germ cell tumors, J. Clin. Oncol., 31 Bartkova, 2003, Deregulation of the RB pathway in human testicular germ cell tumours: RB pathway defects in testicular cancer, J. Pathol., 200, 149, 10.1002/path.1353 Beviglia, 1997, Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression, Int. J. Cancer, 74, 301, 10.1002/(SICI)1097-0215(19970620)74:3<301::AID-IJC12>3.0.CO;2-E Bokemeyer, 1996, Expression of stem-cell factor and its receptor c-kit protein in normal testicular tissue and malignant germ-cell tumours, J. Cancer Res. Clin. Oncol., 122, 301, 10.1007/BF01261407 Bokemeyer, 2007, Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer study Group, Ann. Oncol., 19, 448, 10.1093/annonc/mdm526 Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors. Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT01851200. Castillo-Avila, 2009, Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors, Clin. Cancer Res., 15, 3384, 10.1158/1078-0432.CCR-08-2170 Cecchi, 2010, Targeting the HGF/Met signalling pathway in cancer, Eur J Cancer Oxf Engl 1990, 46, 1260 Cierna, 2016, Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors, Ann. Oncol., 27, 300, 10.1093/annonc/mdv574 Di Vizio, 2005, Loss of the tumor suppressor gene PTEN marks the transition from intratubular germ cell neoplasias (ITGCN) to invasive germ cell tumors, Oncogene, 24, 1882, 10.1038/sj.onc.1208368 Durán, 2010, Expression of EGFR, HER-2/neu and KIT in germ cell tumours, Clin. Transl. Oncol., 12, 443, 10.1007/s12094-010-0532-6 Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers. Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT02034110. Einhorn, 1997, Testicular cancer: an oncological success story, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 3, 2630 Einhorn, 2006, Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT, Am. J. Clin. Oncol., 29, 12, 10.1097/01.coc.0000195086.47548.ef Einhorn, 2007, High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors, N. Engl. J. Med., 357, 340, 10.1056/NEJMoa067749 Fankhauser, 2015, Frequent PD-L1 expression in testicular germ cell tumors, Br. J. Cancer, 113, 411, 10.1038/bjc.2015.244 Feldman, 2010, TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis, J. Clin. Oncol., 28, 1706, 10.1200/JCO.2009.25.1561 Feldman, 2010, Phase II trial of sunitinib in patients with relapsed or refractory germ cell tumors, Invest. New Drugs, 28, 523, 10.1007/s10637-009-9280-2 Feldman, 2013, A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors, Invest. New Drugs, 31, 1016, 10.1007/s10637-013-9934-y Fenner, 2019, Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer study Group, J. Cancer Res. Clin. Oncol., 145, 717, 10.1007/s00432-018-2752-z Fukuda, 1999, Expression of vascular endothelial growth factor in patients with testicular germ cell tumors as an indicator of metastatic disease, Cancer, 85, 1323, 10.1002/(SICI)1097-0142(19990315)85:6<1323::AID-CNCR15>3.0.CO;2-G Gandaglia, 2014, Long-term survival in patients with germ cell testicular cancer: a population-based competing-risks regression analysis, Eur. J. Surg. Oncol. EJSO., 40, 103, 10.1016/j.ejso.2013.09.019 Guggenheim, 2008, Poly (ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA, Bioorg. Med. Chem., 16, 10121, 10.1016/j.bmc.2008.09.074 Harbour, 1999, Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1, Cell, 98, 859, 10.1016/S0092-8674(00)81519-6 Hechelhammer, 2003, Epidermal growth factor receptor is a marker for syncytiotrophoblastic cells in testicular germ cell tumors, Virchows Arch., 443, 28, 10.1007/s00428-003-0835-x Izquierdo, 1995, Differential expression of the c-kit proto-oncogene in germ cell tumours, J. Pathol., 177, 253, 10.1002/path.1711770307 Jain, 2014, Phase II clinical trial of oxaliplatin and Bevacizumab in refractory germ cell tumors, Am. J. Clin. Oncol., 37, 450, 10.1097/COC.0b013e31827de90d Juliachs, 2013, ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor: ErbB3 expression in testicular GCTs, Int. J. Cancer, 133, 235, 10.1002/ijc.28009 Juliachs, 2013, Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors, BMC Cancer [Internet], 13 Keir, 2008, PD-1 and its ligands in tolerance and immunity, Annu. Rev. Immunol., 26, 677, 10.1146/annurev.immunol.26.021607.090331 Kemmer, 2004, KIT mutations are common in testicular seminomas, Am. J. Pathol., 164, 305, 10.1016/S0002-9440(10)63120-3 Kollmannsberger, 1999, Cisplatin-refractory, HER2/neu-expressing germ-cell cancer: induction of remission by the monoclonal antibody Trastuzumab, Ann Oncol Off J Eur Soc Med Oncol., 10, 1393, 10.1023/A:1008365216323 Kollmannsberger, 2002, Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer, Cancer, 95, 301, 10.1002/cncr.10671 Kollmannsberger, 2002, Activity of Oxaliplatin in Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer: A Study of the German Testicular Cancer Study Group, J. Clin. Oncol., 20, 2031, 10.1200/JCO.2002.08.050 Lail-Trecker, 1998, A role for hepatocyte growth factor/scatter factor in regulating normal and neoplastic cells of reproductive tissues, J. Soc. Gynecol. Investig., 5, 114 LEE011 for patients with CDK4/6 pathway activated tumors (SIGNATURE). Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT02187783. Loehrer, 1998, Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor, J. Clin. Oncol., 16, 2500, 10.1200/JCO.1998.16.7.2500 Madani, 2003, Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors, Ann. Oncol Off. J. Eur. Soc. Med. Oncol., 14, 873, 10.1093/annonc/mdg244 Mego, 2007, Bevacizumab in a growing teratoma syndrome. Case report, Ann. Oncol., 18, 962, 10.1093/annonc/mdm125 Mego, 2013, PARP expression in germ cell tumours, J. Clin. Pathol., 66, 607, 10.1136/jclinpath-2012-201088 Mego, 2016, Phase II study of everolimus in refractory testicular germ cell tumors, Urol Oncol Semin Orig Investig., 34, 122.e17, 10.1016/j.urolonc.2015.10.010 Moroni, 2001, Epidermal growth factor receptor expression and activation in nonseminomatous germ cell tumors, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 7, 2770 Motzer, 1992, Ifosfamide-based chemotherapy for patients with resistant germ cell tumors: the Memorial Sloan-Kettering Cancer center experience, Semin. Oncol., 19, 8 Murphy, 1993, Surgical salvage of chemorefractory germ cell tumors, J. Clin. Oncol., 11, 324, 10.1200/JCO.1993.11.2.324 Necchi, 2016, An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): results at the end of first stage (FM12GCT01), J. Clin. Oncol., 34 Necchi, 2017, Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial, Ann. Oncol., 28, 1346, 10.1093/annonc/mdx124 Nieto, 2015, Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors, Ann. Oncol., 26, 2125, 10.1093/annonc/mdv310 Nikolaou, 2007, Kit expression in male germ cell tumors, Anticancer Res., 27, 1685 Nivolumab and Ipilimumab in Treating Patients with Rare Tumors. Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT02834013. Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors. Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT03726281. Oechsle, 2010, Lenalidomide in patients with cisplatin-refractory and multiply relapsed germ cell tumors, J. Cancer Res. Clin. Oncol., 136, 165, 10.1007/s00432-009-0677-2 Oechsle, 2011, Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors, Eur. Urol., 60, 850, 10.1016/j.eururo.2011.06.019 Oechsle, 2011, Preclinical and clinical activity of sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian Urologic Oncology Group/German Testicular Cancer Study Group cooperative study, Ann. Oncol., 22, 2654, 10.1093/annonc/mdr026 Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor. Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT02533765. Olivarez, 1994, Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease, Cancer Res., 54, 2800 Oosterhuis, 2005, Testicular germ-cell tumours in a broader perspective, Nat. Rev. Cancer, 5, 210, 10.1038/nrc1568 Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors. Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT01743482. Pectasides, 2008, Complete response after imatinib mesylate administration in a patient with chemoresistant stage IV seminoma, Anticancer Res., 28, 2317 Pedersini, 2007, Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT, Lancet Oncol., 8, 1039, 10.1016/S1470-2045(07)70344-3 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic. Avalible from: https://www.clinicaltrials.gov/ct2/show/NCT02721732. Piulats, 2007, Phase II multicenter study of imatinib in patients with chemorefractory germ cell tumors that express c-kit, Cancer Res. Rick, 2006, Activity of thalidomide in patients with platinum-refractory germ-cell tumours, Eur. J. Cancer, 42, 1775, 10.1016/j.ejca.2006.03.013 Sánchez-Muñoz, 2012, Targeted therapies in the treatment of germ cell tumors: the need for new approaches against “orphan” tumors, Crit. Rev. Oncol. Hematol., 83, 444, 10.1016/j.critrevonc.2011.12.001 Skoneczna, 2014, Sorafenib monotherapy in patients with inoperable/recurrent germcell tumors (GCT) refractory to chemotherapy: phase II study, J. Clin. Oncol., 32 Soule, 2002, HER-2/neu expression in germ cell tumours, J. Clin. Pathol., 55, 656, 10.1136/jcp.55.9.656 Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors. Avalible from: https://clinicaltrials.gov/ct2/show/NCT02375204. Strohmeyer, 1991, Correlation between retinoblastoma gene expression and differentiation in human testicular tumors, Proc. Natl. Acad. Sci. U. S. A., 88, 6662, 10.1073/pnas.88.15.6662 Strohmeyer, 1995, Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue, J. Urol., 153, 511, 10.1097/00005392-199502000-00073 Sturgeon, 2011, Non–Risk-Adapted Surveillance in Clinical Stage I Nonseminomatous Germ Cell Tumors: The Princess Margaret Hospital’s Experience, Eur. Urol., 59, 556, 10.1016/j.eururo.2010.12.010 Subbiah, 2014, Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial, J. Hematol. OncolJ Hematol Oncol [Internet], 7 Tandstad, 2009, Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular Cancer: the SWENOTECA management program, J. Clin. Oncol., 27, 2122, 10.1200/JCO.2008.18.8953 Vaughn, 2009, Treatment of growing teratoma syndrome, N. Engl. J. Med., 360, 423, 10.1056/NEJMc0808558 Vaughn, 2015, Phase 2 trial of the cyclin-dependent kinase 4/6 inhibitor palbociclib in patients with retinoblastoma protein-expressing germ cell tumors: phase 2 Trial of Palbociclib for GCT, Cancer, 121, 1463, 10.1002/cncr.29213 Viglietto, 1996, Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor, Oncogene, 13, 577 Voigt, 2006, Bevacizumab plus high-dose ifosfamide, etoposide and carboplatin (HD-ICE) as third-line salvage chemotherapy induced an unexpected dramatic response in highly platinum refractory germ-cell cancer, Ann. Oncol., 17, 531, 10.1093/annonc/mdj028 Wang, 2009, Epidermal growth factor receptor protein expression and gene amplification in the chemorefractory metastatic embryonal carcinoma, Mod. Pathol., 22, 7, 10.1038/modpathol.2008.133 Zschäbitz, 2017, Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation, Eur. J. Cancer, 76, 1, 10.1016/j.ejca.2017.01.033